Organization | Philips

Philips Report issue

For profit Phase 1 Phase 2

Founded: Eindhoven Netherlands (1891)

Status: Acquired by Solvay (1990) → now Abbott (2009)

Organization Overview

First Clinical Trial

2007

NCT00563212

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2022

Timeline

NOW

Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Icadom | Philips BioTelemetry Research | Philips (China) Investment CO., LTD | Philips Clinical & Medical Affairs Global | Philips-Duphar | Philips Electronics Nederland BV | Philips Electronics Nederland B.V. acting through Philips CTO organization | Philips GmbH Market DACH | Philips Healthcare | Philips Light and Health | Philips Portuguesa S.A. | Philips Research | Philips Research Eindhoven | Philips Respironics | Phillips-Medisize

Active Ingredients

Drugs in Phase 2 Trials (3)

cxa-10 (1 trial)

letrozole (femara) (1 trial)

ribociclib (kisqali) (1 trial)

Drugs in Phase 1 Trials (4)

13c-pyruvate (1 trial)

23-valent pneumococcal polysaccharide vaccine (pneumovax-23) (1 trial)

interferon gamma-1b (actimmune) (1 trial)

typhoid vi polysaccharide vaccine (Typhim Vi) (1 trial)

Drugs in Other Trials (6)

Key: Philips (4) Acquired (2)

2-butanol (1 trial)

indocyanine green (ic-green) (1 trial)

insulin human (humulin) (1 trial)

naltrexone (revia) (1 trial)

sodium chloride (1 trial)

vitamin d3 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Breast Neoplasms (Phase 2)

Fibrosis (Phase 1)

Glioma (Phase 1)

Hypertension (Phase 2)

Idiopathic Pulmonary Fibrosis (Phase 1)

Pulmonary Fibrosis (Phase 1)

Overview

Highest Phase: Phase 2
# of Trials: 10
# of Trial APIs: 13